Interstitial cystitis: A primary care perspective

**ABSTRACT**

Interstitial cystitis is more common than previously thought and is often diagnosed only when pain, frequency, and urgency become continuous and severe. Its diagnosis is straightforward, and effective therapies are available. Physicians should keep the diagnosis of interstitial cystitis in mind for all patients presenting with pelvic pain or urinary symptoms.

**KEY POINTS**

Overly restrictive diagnostic criteria identify only patients with severe and advanced disease and have led to missed diagnosis and underreporting of this debilitating condition.

Symptoms of interstitial cystitis include urinary urgency and frequency, pelvic pain at various locations, nocturia, and dyspareunia.

The clinical presentation of interstitial cystitis has been well characterized and its symptoms can be quantified with validated, brief questionnaires. Although the diagnosis can often be made empirically on the basis of symptoms alone, office-based diagnostic tools now enable the physician to diagnose the disease with confidence.

Conservative therapies relieve symptoms and address the underlying cause of the disease in most patients. Referral to a specialist is necessary only for patients with refractory disease.

**MORE COMMON THAN THOUGHT**

Interstitial cystitis is a chronic condition of the lower urinary tract that causes urinary urgency and frequency, pelvic pain, or both. Untreated, it may progress to severe, continuous symptoms resulting in a substantially compromised quality of life and permanent tissue damage. The primary care patient population may include many women and men who have interstitial cystitis and are not yet diagnosed.

Historically, interstitial cystitis was considered rare, difficult to diagnose, and difficult to treat. Recent data, however, show that it is more common than previously thought, and physicians now have validated diagnostic tools to detect it in patients whose symptoms were previously unrecognized or misdiagnosed. In addition, effective treatments exist that can relieve symptoms in a number of cases. The primary care physician can initiate conservative measures that are appropriate and effective for many patients, leaving only refractory cases to the specialist.
its attendant excruciating pain, urgency, and frequency, but the key is to recognize the disease in the same patient years earlier, when symptoms are insidiously progressing and intermittent. Depending on their sex and their symptom pattern, patients in the earlier phases of interstitial cystitis may receive diagnoses such as chronic pelvic pain, endometriosis, or recurrent urinary tract infections before their interstitial cystitis is discovered.

POTASSIUM PROVOKES SYMPTOMS

The pathophysiology of interstitial cystitis may involve a number of factors. Possible causes include an autoimmune disorder or neurogenic abnormalities.

Growing evidence indicates that interstitial cystitis is associated with abnormal epithelial permeability in the lower urinary tract. Normally, the bladder epithelium is coated with a glycosaminoglycan-containing mucous layer, which protects it from irritants in the urine. The dysfunctional epithelium loses this barrier, increasing its permeability to damaging urinary solutes.

In particular, potassium appears to be a major factor in provoking symptoms and producing tissue injury. When Parsons et al instilled potassium chloride into the bladders of 231 patients with interstitial cystitis and 41 normal subjects, the potassium induced symptoms of urgency and pain in 75% of the patients with interstitial cystitis, but not in the normal subjects unless the bladder mucosa had been injured with protamine. Potassium absorption correlated with symptoms; instilling heparin reversed the symptoms and potassium absorption. These findings led to development of the potassium sensitivity test, a specific and sensitive office-based procedure that will be described in the following sections.

SYMPTOMS PROGRESS SLOWLY

Interstitial cystitis tends to exist as a continuum that spans decades of life, with symptoms gradually progressing from mild and intermittent to severe and constant.

The clinical presentation is variable.
Most cases have an insidious onset, although the disease can present suddenly. Most patients have urgency, frequency, and pain, but some have only pain and others only urgency. A patient may not report or even perceive urinary frequency. It is not always obvious that the bladder is the source of a patient's symptoms, because pain of bladder origin refers throughout the pelvis. Pain with sexual activity is common in men and women with interstitial cystitis.

Flares of symptoms may last several days and involve significant urgency and pain that may be misdiagnosed as a urinary tract infection. For both women and men, flares can be triggered by sexual activity or activation of allergies. Women may have flares during the premenstrual week.

**Red flags.** Interstitial cystitis should be considered if a patient presents with any of the following:
- Pelvic pain (although pain is not always present in interstitial cystitis, most patients with interstitial cystitis do present with pain)
- Dyspareunia (pain with sexual intimacy)
- Frequent urinary tract infections
- Frequent vaginitis
- Nighttime urination
- Urinary frequency.

---

**Pelvic Pain and Urgency/Frequency (PUF) symptom scale**

Please circle the answer that best describes how you feel for each question below.

<table>
<thead>
<tr>
<th>Question</th>
<th>Options</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 How many times do you go to the bathroom during the day?</td>
<td>3–6, 7–10, 11–14, 15–19, 20+</td>
<td></td>
</tr>
<tr>
<td>2a. How many times do you go to the bathroom at night?</td>
<td>0, 1, 2, 3, 4+</td>
<td></td>
</tr>
<tr>
<td>b. If you get up at night to go to the bathroom, does it bother you?</td>
<td>Never, Occasionally, Usually, Always</td>
<td></td>
</tr>
<tr>
<td>3 Are you currently sexually active?</td>
<td>Yes, No</td>
<td></td>
</tr>
<tr>
<td>4a. If you are sexually active, do you now have or have you ever had pain or symptoms during or after sexual activity?</td>
<td>Never, Occasionally, Usually, Always</td>
<td></td>
</tr>
<tr>
<td>b. If you have pain, does it make you avoid sexual activity?</td>
<td>Never, Occasionally, Usually, Always</td>
<td></td>
</tr>
<tr>
<td>5 Do you have pain associated with your bladder or in your pelvis (vagina, labia, lower abdomen, urethra, perineum, penis, testes, or scrotum)?</td>
<td>Never, Occasionally, Usually, Always</td>
<td></td>
</tr>
<tr>
<td>6a. If you have pain, is it usually</td>
<td>Mild, Moderate, Severe</td>
<td></td>
</tr>
<tr>
<td>b. Does your pain bother you?</td>
<td>Never, Occasionally, Usually, Never</td>
<td></td>
</tr>
<tr>
<td>7 Do you still have urgency after you go to the bathroom?</td>
<td>Never, Occasionally, Usually, Always</td>
<td></td>
</tr>
<tr>
<td>8a. If you have urgency, is it usually</td>
<td>Mild, Moderate, Severe</td>
<td></td>
</tr>
<tr>
<td>b. Does your urgency bother you?</td>
<td>Never, Occasionally, Usually, Always</td>
<td></td>
</tr>
</tbody>
</table>

**SYMPTOM SCORE (1, 2a, 4a, 5, 6a, 7, 8a)—SUBTOTAL**

**BOTHER SCORE (2b, 4b, 6b, 8b)—SUBTOTAL**

**TOTAL SCORE (symptom score + bother score)**

---

FIGURE 1
■ EVALUATION IS OFFICE-BASED

The evaluation of a patient with urinary urgency and frequency and pelvic pain includes a thorough history and physical examination (Table 1), as with any primary care patient.

The physical examination concentrates on the lower abdomen and pelvis. In women, a vaginal examination is important, particularly to test for tenderness at the anterior vaginal wall (bladder base). In men, any pain in the perineum or the prostate upon digital rectal examination may indicate interstitial cystitis.

Urinalysis is essential for any patient who presents with urgency and frequency or pelvic pain regardless of the physician’s impression based on the presenting symptoms. Urine microscopy can rule out hematuria, kidney stones, and bacteriuria. Although the symptoms of interstitial cystitis can be confused with those of urinary tract infections, to date no evidence exists for an infectious agent in interstitial cystitis. Blood in the urine mandates an evaluation for genitourinary cancer. In patients

---

**Procedure for the potassium sensitivity test**

Drain bladder
Insert small urethral catheter
Instill 40 mL of water slowly over 2–3 minutes
Rank urgency (0–5)
Rank pain (0–5)
Drain bladder
Instill 40 mL of a solution of 0.4-mol/L potassium chloride

If no immediate reaction
Allow to remain 5 minutes
Rank urgency (0–5)
Rank pain (0–5)

If neither has increased by ≥ 2 points
Negative test
Drain bladder

If immediate pain

If either has increased by ≥ 2 points
Positive test
Drain bladder
Wash with 60 mL of water
Instill rescue therapy (heparin 10,000–40,000 U, lidocaine 1% 10 mL, sodium bicarbonate 8.4% 3 mL)


**Figure 2**
at high risk, urine cytologic study may be used to exclude carcinoma in situ of the bladder.

Other testing, such as evaluation for sexually transmitted diseases, pelvic ultrasonography, or computed tomography, may be necessary, depending on clinical circumstances.

The Pelvic Pain and Urgency/Frequency (PUF) scale, a validated questionnaire that quantifies the patient’s symptoms (FIGURE 1), is useful for identifying interstitial cystitis. Patients with higher scores on the PUF—reflecting multiple and more pronounced symptoms—have a greater likelihood of a positive result if they undergo a potassium sensitivity test (see below).

The potassium sensitivity test is an optional method that can be used to help confirm the suspicion of interstitial cystitis (FIGURE 2). It is designed to detect dysfunction of the bladder epithelium using potassium as an irritant: a solution of potassium chloride is instilled to determine if it provokes pain or urgency.

Parsons reviewed results of this test from centers around the world and found that 1,746 (78%) of 2,234 patients with suspected interstitial cystitis had a positive test. A positive test indicates epithelial dysfunction, which is seen in patients with radiation cystitis or an acute urinary tract infection as well as in interstitial cystitis. However, patients with chronic urinary tract infections, bladder outlet obstruction, or overactive bladder have a low rate of response to intravesical potassium.

The potassium sensitivity test is as well tolerated as other common office-based procedures. In a survey, 111 patients who underwent the test judged the discomfort to be equal to or less than that of standard procedures such as a Papnicolau (Pap) smear or digital rectal examination. Among patients who had undergone both procedures, the percentages who reported greater discomfort with the potassium sensitivity test were 8% vs a Pap smear, 10% vs a digital rectal examination, 5% vs a mammogram, and 21% vs a blood draw. The potassium sensitivity test is as easy to perform as urethral catheterization.

To avoid inflicting pain needlessly, the decision to perform the test should be thoughtfully considered for each patient. When the test is properly administered, an anesthetic solution is given quickly to minimize any discomfort.

Urodynamic testing and cystoscopy are not necessary to diagnose interstitial cystitis. Traditionally, cystoscopy and hydrodistention have been considered essential for diagnosis, but no reports in the peer-reviewed literature have demonstrated their sensitivity and specificity for diagnosing interstitial cystitis.

### VARIOUS TREATMENTS AVAILABLE

Various behavioral, pharmacologic, and interventional treatments are available for interstitial cystitis.

**Behavioral treatment**

Behavioral treatment is centered around changing a stressful lifestyle and excluding possible dietary irritants. Foods that cause irritation include caffeine-containing substances (eg, coffee, chocolate), citrus fruits (including juices), alcohol, tomatoes, and carbonated beverages. However, each patient is different. Keeping a diary of foods consumed and symptoms that occur may help patients identify the culprit. As a general rule, foods rich in potassium are problematic.

**Pharmacologic treatment**

Pharmacologic treatment for interstitial cystitis has several components (TABLE 2).

**Amitriptyline** is used to increase the pain threshold. Interstitial cystitis is a symptom complex, and pain is generally the worst symptom.)

**Hydroxyzine** can be used as a mast cell stabilizer, as the inflammatory response associated with interstitial cystitis is thought to be driven by histamine release from the mast cells.

**Pentosan polysulfate sodium** (PPS) has become a cornerstone of treatment of interstitial cystitis, owing to its ability to restore the integrity of the mucous layer. Currently, it is the only oral medication approved for treating interstitial cystitis in the United States. The molecular structure of PPS is similar to that of the glycosaminoglycans in the bladder surface mucus, and the drug is
believed to help restore the mucous layer to reestablish impermeability to urine solutes. Several long-term clinical studies showed PPS to be effective in treating interstitial cystitis. Adverse effects tended to be mild, infrequent, and transient, the most common being alopecia, diarrhea, nausea, headache, rash, dyspepsia, and abdominal pain.

PPS is more beneficial the longer it is used, and patients who understand this are more likely to comply with the treatment regimen.

The standard dosage is 100 mg three times a day, given 1 hour before or 2 hours after a meal. PPS can be coupled with hydroxyzine or amitriptyline for symptom relief in severe or advanced cases.

Interventional treatment

Patients with interstitial cystitis may benefit from intravesical instillation of therapeutic solutions.

Dimethyl sulfoxide was approved by the US Food and Drug Administration for use in interstitial cystitis and is reported to provide good to excellent symptom relief in at least 50% of patients. Newer solutions include the combination of PPS or heparin with lidocaine and sodium bicarbonate (Table 2). In a preliminary study, the intravesical solution relieved symptoms significantly and immediately in 41 (75%) of 55 patients with interstitial cystitis. Patients can easily be taught to perform instillations at home.

Cystoscopy with hydrodistention may offer some symptomatic relief, but it is not proven in the treatment of interstitial cystitis. Bladder resection should be considered only if the disease is completely refractory to treatment.

CLOSE FOLLOW-UP IS ESSENTIAL

In caring for patients with interstitial cystitis, the most important tasks are to discover the correct diagnosis and prescribe appropriate treatment. By the time interstitial cystitis is diagnosed, many patients have had progressive disease and associated symptoms for a considerable time. Symptoms may take months or even up to 2 years to improve maximally with treatment. Appropriate therapy can result in substantial medical cost.

| TABLE 2 |

Conservative treatment of interstitial cystitis

- Pentosan polysulfate sodium (PPS) 100 mg three times day
- Hydroxyzine (if needed) 25 mg at bedtime, increase to 50–100 mg/day during allergy season
- Amitriptyline (if needed) 25 mg at bedtime, increase to 50 mg/day after 1–2 months

Intravesical therapeutic solution 3–7 times a week for at least 2 weeks (for immediate, temporary symptom relief at start of treatment or for symptom flares)

Patients can be taught to administer at home

Mix together the following, instill into an empty bladder, and retain for approximately 30 minutes

- Pentosan polysulfate sodium 100–200 mg (one or two 100-mg oral capsules, each dissolved in 10 mL buffered normal saline) or heparin 10,000–40,000 U (to aid in repair and restoration of bladder mucus)
- Lidocaine 1% 10 mL or 2% 16 mL (as an anesthetic)
- Sodium bicarbonate 8.4% 3 mL (to increase absorption of lidocaine)

Evaluate at 3–6 months after start of treatment

- If responding, continue treatment
- If not responding, refer for further urologic workup, including cystoscopy

Once treatment is started, symptoms may take up to 2 years to resolve
savings, for example, by preventing unneces-
sary surgery.

Close follow-up is essential. To ensure
that treatment is as effective as possible, we
follow up with our patients monthly for the
first 3 months and then every 3 months there-
after. Frequent follow-up enables us to
improve compliance, titrate medications, and
reinforce behavioral modifications such as
dietary changes.

REFERENCES
1. Metts JF. Interstitial cystitis: urgency and frequency syndrome. Am
Fam Physician 2001; 64:1199–1214.
2. Driscoll A, Teichman JMH. How do patients with interstitial cystitis
3. Koziol JA, Clark DC, Gittes RF, Tan EM. The natural history of intersti-
4. Parsons CL. Interstitial cystitis. In: Teichman JMH, editor; Weiss BD,
series editor. 20 Common Problems in Urology. New York, NY:
5. Parsons CL, Dell J, Stanford EJ, et al. Increased prevalence of intersti-
tial cystitis: previously unrecognized urologic and gynecologic cases
identified using a new symptom questionnaire and intravesical
6. Curhan GC, Speizer FE, Hunter DJ, Curhan SG, Stampfer MJ.
Epidemiology of interstitial cystitis: a population based study. J Urol
1999; 161:549–552.
Presented at: Research Insights Into Interstitial Cystitis: A Basic and
Clinical Science Symposium; October 30–November 1, 2003;
Alexandria, Va.
8. Dell JR. Use of the PUF questionnaire to determine the prevalence of
IC in obstetrics and gynecology practices. Presented at: Research
Insights Into Interstitial Cystitis: A Basic and Clinical Science
9. Rosenberg MT, Page S, Roth L, Areaux D, Thallman C, Kval TE.
Identification of interstitial cystitis in women in a primary care set-
ting using a symptom questionnaire and potassium sensitivity test-
ing. Presented at: Research Insights Into Interstitial Cystitis: A Basic and
Clinical Science Symposium; October 30–November 1, 2003;
Alexandria, Va.
10. Rosenberg MT, Hazzard MA. Prevalence of interstitial cystitis symp-
toms in women: a population-based study in the primary care office.
11. Gillenwater JY, Wein AJ. Summary of the National Institute of
Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on
Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland,
12. Sant GR, Theoharides TC. The role of the mast cell in interstitial cysti-
13. Hurst RE. Structure, function, and pathology of proteoglycans and
14. Parsons CL, Lilly JD, Stein P. Epithelial dysfunction in nonbacterial cysti-
15. Parsons CL, Greenberger M, Gabal L, Bidair M, Barme G. The role of
urinary potassium in the pathogenesis and diagnosis of interstitial
16. Parsons CL, Zupkas P, Parsons JK. Intravesical potassium sensitivity in
patients with interstitial cystitis and urethral syndrome. Urology
17. Parsons CL, Albo M. Intravesical potassium sensitivity in patients with
18. Parsons CL. Prostatitis, interstitial cystitis, chronic pelvic pain, and
urethral syndrome share a common pathophysiology: lower urinary
dysfunctional epithelium and potassium recycling. Urology 2003;
19. Rosenberg MT, Page SA, Roth L, Areaux D, Thallman C, Kval TE.
Tolerability of the potassium sensitivity test for interstitial cystitis.
Presented at: Research Insights Into Interstitial Cystitis: A Basic and
Clinical Science Symposium; October 30–November 1, 2003;
Alexandria, Va.
20. Pontari MA. Use of cystoscopy, bladder biopsy and hydrodistension in
the diagnosis and treatment of interstitial cystitis. Presented at:
Research Insights Into Interstitial Cystitis: A Basic and Clinical Science
Symposium; October 30–November 1, 2003; Alexandria, Va.
21. Hanno PM, Buehler J, Wein AJ. Use of amitriptyline in the treatment of
22. Parsons CL. Epithelial coating techniques in the treatment of intersti-
tial cystitis. Urology 1997; 49(suppl 5A):100–104.
23. Parsons CL, Mulholland SG. Successful therapy of interstitial cystitis
24. Mulholland SG, Hanno P, Parsons CL, Sant GR, Staskin DR. Pentosan
polysulfate sodium for therapy of interstitial cystitis: a double-blind
quantitatively controlled method to study prospectively interstitial
cystitis and demonstrate the efficacy of pentosanpolysulfate. J Urol
1993; 150:845–848.
26. Hanno PM. Analysis of long-term Elmiron therapy for interstitial cys-
28. Elmiron (pentosan polysulfate sodium capsules) prescribing informa-
29. Parsons CL. Current strategies for managing interstitial cystitis. Exp
30. Sant GR. Intravesical 50% dimethyl sulfoxide (Rimso-50) in treatment
31. Moldwin RM, Sant GR. Interstitial cystitis: a pathophysiology and

ADDRESS: Matt Rosenberg, MD, Mid-Michigan Health Centers, 214 North
West Avenue, Jackson, MI 49201; e-mail mattricoren@yahoo.com.